TY - JOUR
T1 - Glucagon and diabetes
AU - Raskin, Philip
AU - Unger, Roger H
N1 - Funding Information:
':'Assistant Professor, University of Texas Southwestern Medical School; Clinical Investi-gator, V A Hospital, Dallas, Texas ''''Professor of Internal Medicine. University of Texas Southwestern Medical School; Staff Physician, V A Hospital, Dallas, Texas This work is supported by VA Institutional Research Support Grant 549-8000-01 and NIH Grants AM 02700-16, I-ROI-AM 18179, and I-MOI-RR 00633.
PY - 1978
Y1 - 1978
N2 - We have considered the evidence, first that the presence of glucagon is essential in the pathogenesis of the full syndrome that results from complete insulin deficiency; second, that in the diabetic in whom insulin levels are relatively fixed, a rise in glucagon concentration contributes to endogenous hyperglycemia; and, third, that conventional methods of treatment of diabetes do not fully correct either the abnormal glucagon levels or the hyperglycemia, but when insulin therapy is supplemented with somatostatin, an agent which suppresses both glucagon and growth hormone, both hyperglycemia and hyperglucagonemia are corrected. These facts may one day provide a rationale for therapeutic efforts to suppress excess glucagon secretion in the management of diabetes in man.
AB - We have considered the evidence, first that the presence of glucagon is essential in the pathogenesis of the full syndrome that results from complete insulin deficiency; second, that in the diabetic in whom insulin levels are relatively fixed, a rise in glucagon concentration contributes to endogenous hyperglycemia; and, third, that conventional methods of treatment of diabetes do not fully correct either the abnormal glucagon levels or the hyperglycemia, but when insulin therapy is supplemented with somatostatin, an agent which suppresses both glucagon and growth hormone, both hyperglycemia and hyperglucagonemia are corrected. These facts may one day provide a rationale for therapeutic efforts to suppress excess glucagon secretion in the management of diabetes in man.
UR - http://www.scopus.com/inward/record.url?scp=0018187887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018187887&partnerID=8YFLogxK
U2 - 10.1016/S0025-7125(16)31767-9
DO - 10.1016/S0025-7125(16)31767-9
M3 - Article
C2 - 355737
AN - SCOPUS:0018187887
SN - 0025-7125
VL - 62
SP - 713
EP - 722
JO - Medical Clinics of North America
JF - Medical Clinics of North America
IS - 4
ER -